The news: Novo Nordisk secured an important legal victory against pharmacies making compounded forms of Ozempic and Wegovy.
A Texas federal court denied a compounding pharmacy trade association's motion to freeze the FDA's decision to end the shortage of semaglutide (marketed as Ozempic and Wegovy). The group unsuccessfully argued that there is still a shortage of the drug.
Why it matters: The hits keep coming to companies that have been selling cheaper, copycat versions of brand-name GLP-1 weight loss drugs that were in short supply.